Timothy Quinn, MD
Family Medicine · Ridgeland, MSNPI 1447350483
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,575 of the $22,523 with a category attached, or 69.2%. 26 manufacturers reported payments, led by Exact Sciences at 40.0% of the total. Reporting peaked in 2023 at $9,866 and has fallen 54.0% since, to $4,540 in 2025. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 119 payments — averaging $189.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Exact Sciences$9K
- Pfizer$5K
- Lilly USA, LLC$4K
- Novo Nordisk$2K
- Scynexis, Inc.$926
- Welch Allyn$648
- plus $939 from 20 others
Across 96 payments — averaging $84,298 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$7.3M
- Merck$402K
- Pfizer$345K
What the payments were for
- Consulting fees$15,57569%
- Speaking & faculty fees$8884%
- Travel & lodging$2,0789%
- Food & beverage$3,23814%
- Gifts$6483%
- Other$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Exact Sciences | 7 | $9,019 |
| Pfizer | 9 | $4,944 |
| Lilly USA, LLC | 16 | $4,490 |
| Novo Nordisk | 44 | $1,558 |
| Scynexis, Inc. | 4 | $926 |
| Welch Allyn | 1 | $648 |
| Medtronic(2 entities) | 2 | $200 |
| AstraZeneca | 8 | $124 |
| Baxter Healthcare | 1 | $96 |
| Rhythm Pharmaceuticals, Inc. | 1 | $75 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Amgen(2 entities) | 3 | $45 |
| Abbott | 2 | $42 |
| Hologic Sales And Service, LLC | 2 | $39 |
| Astellas Pharma US Inc | 2 | $38 |
| Genentech USA, Inc. | 2 | $35 |
| Gilead | 1 | $33 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Global Blood Therapeutics, Inc. | 2 | $31 |
| AbbVie | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Boston Scientific | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 2 | $6 |
| Merck | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cologuard Collection Kit$8,895
- SPOT LXI$648
- Ozempic$115
- Wegovy$108
- ZEPBOUND$107
- HawkOne$101
How this compares
$22,523 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 158 | $169,008 |
| EliquisApixaban | 69 | $69,674 |
| MounjaroTirzepatide | 61 | $61,411 |
| JardianceEmpagliflozin | 31 | $54,115 |
| RybelsusSemaglutide | 27 | $46,983 |
| WegovySemaglutide | 20 | $27,931 |
| LinzessLinaclotide | 22 | $21,961 |
| TradjentaLinagliptin | 15 | $20,025 |
| JanuviaSitagliptin Phosphate | 14 | $18,202 |
| TrulicityDulaglutide | 17 | $16,703 |
| XareltoRivaroxaban | 13 | $14,877 |
| MyrbetriqMirabegron | 11 | $11,165 |
| Azelastine Hcl | 155 | $5,915 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,513 |
| Colesevelam Hcl | 16 | $4,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy | $1,558 | $243,922205 claims |
| Lilly USA, LLCMounjaro, Trulicity | $4,490 | $78,11478 claims |
| PfizerEliquis | $4,944 | $69,67469 claims |
| AbbVieLinzess | $26 | $21,96122 claims |
| MerckJanuvia | $5 | $18,20214 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $11,16511 claims |
| AstraZenecaSymbicort | $124 | $4,51314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Ridgeland
- Kristi TrimmRidgeland$34K
- Richard PriceRidgeland$10K
- William LoperRidgeland$9K
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
- Andrea PhillipsJackson$96K
- Tana CooperBiloxi$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.